Why insider trading matters?
If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company was founded in 2012 and is based in New York, New York.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-05-12 | Coleman Mark | Director | Buy | 500 | $58.15 | $29,075 | No |
| 2020-06-29 | Coleman Mark | Director | Buy | 650 | $78.50 | $51,025 | No |
| 2020-06-29 | Pizzie Nick | Chief Financial Officer | Buy | 777 | $76.64 | $59,549 | No |
| 2019-09-26 | Pizzie Nick | Chief Financial Officer | Buy | 2,180 | $24.80 | $54,064 | No |
| 2019-06-26 | Coleman Mark | Director | Buy | 16,200 | $23.10 | $374,280 | No |
| 2019-06-11 | Pizzie Nick | Chief Financial Officer | Buy | 1,920 | $20.80 | $39,936 | No |
| 2019-05-23 | Saad Mark E | Director | Buy | 3,500 | $22.33 | $78,155 | No |
| 2019-05-13 | Coleman Mark | Director | Buy | 4,650 | $21.44 | $99,696 | No |
| 2019-03-19 | Pizzie Nick | Chief Financial Officer | Buy | 5,400 | $12.58 | $67,939 | No |
| 2019-03-19 | Coleman Mark | Director | Buy | 5,100 | $12.18 | $62,118 | No |
| 2018-06-19 | Pizzie Nick | Chief Financial Officer | Buy | 31,000 | $3.10 | $96,080 | No |
| 2015-12-23 | Kaye Randall | Chief Medical Officer | Buy | 1,000 | $9.03 | $9,026 | No |
Insider Smart
Insider Smart